Vorsitz: K. Schäfer (Mainz), K. Stark (München)
(V1797) | Phenotypes of Treatment Resistant Hypertension and their Response to Interventional Renal Denervation | |
K. Fengler, K.-P. Kresoja, K.-P. Rommel, S. Blazek, S. Rosch, C. Lücke, M. Gutberlet, H. Thiele, P. Lurz (Leipzig) | ||
Diskussion | ||
(V1798) | Microplastic particles induce endothelial activation | |
N. Trippel, A.-K. Vlacil, S. Bänfer, R. Jacob, B. Schieffer, K. Grote (Marburg) | ||
Diskussion | ||
(V1799) | The Influence of Rivaroxaban compared to Vitamin K Antagonist treatment upon development of cardiovascular calcification The IRIVASC-Trial | |
R. Stöhr, N. Marx, A. Schuh, V. Brandenburg (Aachen, Würselen) | ||
Diskussion | ||
(V1800) | Protection from immune checkpoint inhibitor-related cardiotoxicity by blockade of tumour necrosis factor alpha | |
L. Michel, U. Hendgen-Cotta, R. Mincu, I. Helfrich, S. Korste, S. Margraf, D. Schadendorf, T. Rassaf, M. Totzeck (Essen, München) | ||
Diskussion | ||
(V1801) | Keynote Lecture: State-of-the-Art: Immune mechanisms in venous and arterial thrombosis |
|
W. Ruf (Mainz) | ||
Diskussion |
10:00 - 11:30 | Pause - Posterdiskussion |